StockData
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc (XFOR) stock

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$2.98−0.11 (-3.56%)

Close on Nov 18, 2026Market cap $295.46MP/E –Yield –

X4 Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

X4 Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$80.39M. For fiscal 2025 it was -$86.88M. The highest annual figure on record is -$22.25M in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$86.88M–
FY2024Dec 31, 2024-$36.40M–
FY2023Dec 31, 2023-$107.52M–
FY2022Dec 31, 2022-$87.57M–
FY2021Dec 31, 2021-$85.11M–
FY2020Dec 31, 2020-$59.87M–
FY2019Dec 31, 2019-$51.70M–
FY2018Dec 31, 2018-$29.09M–
FY2017Dec 31, 2017-$22.25M–
FY2016Dec 31, 2016-$24.35M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$19.99M–
Q2 FY2026Jun 30, 2026-$16.39M–
Q1 FY2026Mar 31, 2026-$20.31M–
Q4 FY2025Dec 31, 2025-$23.70M–
Q3 FY2025Sep 30, 2025-$27.51M–
Q2 FY2025Jun 30, 2025-$26.23M-136.9%
Q1 FY2025Mar 31, 2025-$9.44M–
Q4 FY2024Dec 31, 2024-$35.72M–
Q3 FY2024Sep 30, 2024-$34.50M–
Q2 FY2024Jun 30, 2024$71.10M–
Q1 FY2024Mar 31, 2024-$37.29M–
Q2 FY2023Jun 30, 2023-$25.81M–
Q1 FY2023Mar 31, 2023-$29.30M–
Q4 FY2022Dec 31, 2022-$25.58M–
Q3 FY2022Sep 30, 2022-$20.15M–
Q2 FY2022Jun 30, 2022-$20.57M–
Q1 FY2022Mar 31, 2022-$21.27M–
Q4 FY2021Dec 31, 2021-$29.06M–
Q3 FY2021Sep 30, 2021-$19.12M–
Q2 FY2021Jun 30, 2021-$19.00M–
Q1 FY2021Mar 31, 2021-$17.94M–
Q4 FY2020Dec 31, 2020-$17.66M–
Q3 FY2020Sep 30, 2020-$16.98M–
Q2 FY2020Jun 30, 2020-$14.66M–
Q1 FY2020Mar 31, 2020-$10.58M–
Q4 FY2019Dec 31, 2019-$10.88M–
Q3 FY2019Sep 30, 2019-$16.98M–
Q2 FY2019Jun 30, 2019-$13.41M–
Q1 FY2019Mar 31, 2019-$10.44M–
Q4 FY2018Dec 31, 2018-$8.05M-453.2%
Q3 FY2018Sep 30, 2018-$8.55M–
Q2 FY2018Jun 30, 2018-$6.38M–
Q1 FY2018Mar 31, 2018-$6.11M–
Q4 FY2017Dec 31, 2017$2.28M–
Q3 FY2017Sep 30, 2017-$13.06M–
Q2 FY2017Jun 30, 2017-$5.64M–
Q1 FY2017Mar 31, 2017-$5.83M–

More X4 Pharmaceuticals figures

See a number that looks wrong?